OPALS: A New Osimertinib Adjunctive Treatment of Lung Adenocarcinoma or Glioblastoma Using Five Repurposed Drugs

Background: Pharmacological targeting aberrant activation of epidermal growth factor receptor tyrosine kinase signaling is an established approach to treating lung adenocarcinoma. Osimertinib is a tyrosine kinase approved and effective in treating lung adenocarcinomas that have one of several common...

Descripción completa

Detalles Bibliográficos
Autores principales: Kast, Richard E., Halatsch, Marc-Eric, Rosell, Rafael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Perspective
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8151869/
https://www.ncbi.nlm.nih.gov/pubmed/34068720
http://dx.doi.org/10.3390/cells10051148

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8151869/
https://www.ncbi.nlm.nih.gov/pubmed/34068720
http://dx.doi.org/10.3390/cells10051148

Ejemplares similares